NCT01634919已完成不适用
A Single Center, Prospective Study Evaluating the Anti-fibrotic Effect of Combination Therapy of Peginterferon Alpha-2a Plus Ribavirin in Patients with Chronic Hepatitis C, Based on Histologic Changes and Noninvasive Fibrosis Assessments
Seoul National University Boramae Hospital2 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2012年7月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 55
- 试验地点
- 2
- 主要终点
- Anti-fibrotic response
研究概览
简要总结
•The purpose of this study is to compare the performance between liver biopsy and non-invasive fibrosis assessments evaluating anti-fibrotic efficacy of peginterferon plus ribavirin in patients with hepatitis C pre- and post-treatment
详细描述
- Patients with histologically advanced hepatitis C receiving peginterferon plus ribavirin combination therapy have showed 30-40% of a sustained virologic response (SVR) rate and 50% of histologic improvement.
- The histologic change of liver is the most important prognosticator to predict further clinical outcomes in advanced hepatitis C patients following peginterferon-based antiviral therapy.
- Although liver biopsy remains the gold standard for histologic assessment, it has several shortcomings in terms of poor repeatability due to its invasiveness and poor reproducibility due to sampling error and intra- or inter-observer variability.
- Treatment-naïve patients with chronic hepatitis C will receive PEGASYS® 180 mcg once weekly and ribavirin twice daily for 24 or 48 weeks depending on the genotype of hepatitis C virus (HCV).
- All subjects will be followed for up to 48 weeks after treatment cessation.
- Liver biopsy will be done at baseline and the end of follow-up for the evaluation of histologic response.
- Noninvasive tests for liver fibrosis (ARFI elastography, APRI, FIB-4, FibroTest®, and ELF test) will be assessed per 24 weeks during the whole study period.
- The results of this study will provide insight into the histo-physical link between histologic changes and liver stiffness dynamics during and after peginterferon alpha-2a plus ribavirin treatment in patients with advanced hepatitis C.
- Therefore, noninvasive fibrosis assessments may be useful to trace fibrosis outcomes in patients with advanced hepatitis C receiving antiviral therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects ≥20 years of age
- •Subjects with positive anti-HCV Ab in sera
- •Subjects with detectable HCV RNA by quantitative real time polymerase chain reaction (PCR) (> 50 IU/mL)
- •Subjects without receiving any previous antiviral treatment
- •Subjects undergoing radiologic studies (liver ultrasonography (USG), CT or MRI) to exclude the presence of hepatocellular carcinoma (HCC) within the last 1 year before enrolment
- •All fertile males with partners of childbearing age and females must be using reliable contraception during the study and for 3 months after treatment completion
- •Written informed consent should be obtained from all subjects.
排除标准
- •History of any interferon (IFN)-based therapy before enrolment
- •Positive test at screening for anti-hepatitis A virus (HAV) immunoglobulin M (IgM) Ab, HBsAg, anti-hepatitis D virus (HDV) Ab or anti- HIV Ab
- •Histologically confirmed liver cirrhosis (F4 of fibrosis stage)
- •If subjects have compromised liver function (Child-Pugh score >6)
- •Signs or symptoms of hepatocellular carcinoma within the last 1 year before enrolment
- •History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures, thalassemia)
- •Women with ongoing pregnancy or who are breast feeding
- •Male partner of potentially pregnant women
- •Neutrophil count <1,500 cells/mm3 or platelet count <75,000 cells/mm3 at screening
- •Hemoglobin <11 g/dL for females and <12 g/dL for men at screening
- •Serum creatinine level >1.5 times the upper limit of normal at screening
- •Evidence of immunosuppressive therapy
- •History of severe psychiatric disease, especially depression.(Severe psychiatric disease is defined as major depression or psychosis, suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease)
结局指标
主要结局
Anti-fibrotic response
时间窗: 48 weeks after the end of treatment
Anti-fibrotic response, indicated by a lack of histological worsening, defined as the stabilization or the improvement of at least one stage in the histologic fibrosis staging 48 weeks after the end of treatment
次要结局
- Histologic and noninvasive fibrosis assessments(48 weeks after the end of treatment)
研究者
Won Kim
MD, PhD, Assistant Professor
Seoul National University Boramae Hospital
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
A study of non invasive evaluation of liver fibrosis in patients with Hepatitis B Virus(HBV) monoinfection using Fibroscan (Transient Elastography)Hepatitis B Virus (HBV)Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12609000381280Alfred Hospital250
终止
不适用
Methods to Detect Liver FibrosisLiver FibrosesHepatic SteatosisNCT03027700Children's Hospital Medical Center, Cincinnati6
已完成
不适用
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C InfectionHepatitis C, ChronicNCT01671046Hoffmann-La Roche123
招募中
不适用
Efficacy and Safety of Percutaneous Liver Biopsy With Needle Tract Plugging on Outpatient BasisImage-guided BiopsyLiver BiopsyNCT05614973Yonsei University122
已完成
不适用
Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis BChronic Hepatitis BNCT01679769Peking University First Hospital818